[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Children's Hospital, Zurich\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":490},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,41,65,90,118,146,167,194,218,248,267,288,308,336,362,388,412,439,463],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100624895","the-use-of-cultured-dermal-epithelial-autografts-in-severely-burned-patients-100624895",false,"NCT07415577","The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients","Multicenter Cohort Study for the Use of Cultured Epithelial Autografts (CEA) or Cultured Dermal Epidermal Autografts (CDEA) in Severely Burned Patients","Swisskera","Inclusion Criteria:\n\n* Patients who have undergone treatment at the three Swiss burn centres and received grafts utilizing CEA since the introduction of the CEA technique in Switzerland (from 1985 to 2023) will be invited to participate in this study.\n* Availability of clinical data, including at minimum demographic information and the date and time of CEA\u002FCDEA transplantation.\n* Signed informed consent from the patient or his\u002Fher legal representative\u002Frelatives.\n\nExclusion Criteria:\n\n* Refusal of participation in the study by the patient or his\u002Fher legal representative\u002Frelatives.\n* Patients, who are, of any reason, unable to attend a study visit at one of the study sites or in their home","ALL",{"count":19,"type":20},236,"ESTIMATED","OBSERVATIONAL","The Swisskera project is a multicenter follow-up study at the three Swiss burn centers evaluating long-term outcomes after burn wound coverage with lab-grown epithelial grafts, specifically cultured epithelial autograft (CEA) and, where applicable, cultured dermal-epidermal autograft (CDEA). Patients who received CEA\u002FCDEA between 1985 and 2023 will be invited for a study visit , using available clinical records and standardized long-term scar and skin assessments.\n\nLong-term skin quality will be evaluated by comparing the previously transplanted area with a matched healthy skin reference site using non-invasive measurements (e.g., thickness, transepidermal water loss, hydration, elasticity, and color). Optional small punch biopsies may be obtained from transplanted areas (under local anesthesia or during clinically indicated anesthesia) for histological and immunohistochemical characterization of scar tissue remodeling, including collagen and elastin architecture, vascularization, nerve fiber ingrowth, inflammatory cell patterns, and melanocyte distribution.",[24,25,26,27],"Burn Degree Second","Burn Degree Third","Skin Transplantation","Full Thickness Skin Defects","NOT_YET_RECRUITING","2026-05-20",{"date":31,"type":32},"2026-05-26","ACTUAL",{"date":34,"type":20},"2026-12-01",{"date":36,"type":20},"2030-12-31",{"name":38,"class":39},"University Children's Hospital, Zurich","OTHER",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100265520","genetic-study-of-immunodeficiency-search-for-new-genetic-causes-for-primary-immunodeficiencies-100265520","NCT02735824","Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies","GSI","Inclusion Criteria:\n\n* Patients: Pediatric patients (in\u002Foutpatient or referred) with suspected or confirmed Inborn Errors of Immunity.\n* Relatives: Healthy or affected biological relatives of enrolled patients.\n* Controls: Healthy volunteers with no history of chronic immunological, inflammatory, or infectious disease.\n* Consent: Ability to provide signed informed consent (or guardian consent).",true,{"count":50,"type":20},500,"Individuals with suspected primary immunodeficiency will be studied and the results compared with healthy controls. Primary immunodeficiency may manifest as recurrent, severe or unusual infections as well as signs and symptoms of immune dysregulation such as autoimmunity or lymphoproliferation.",[53,54],"Immunologic Deficiency Syndromes","Primary Immune Deficiency (PID)","RECRUITING","2026-05-11",{"date":58,"type":32},"2026-05-14",{"date":60,"type":32},"2016-02",{"date":62,"type":20},"2027-12",{"name":38,"class":39},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":64},"100451303","short-and-long-arm-fiberglass-cast-immobilization-for-distal-salter-harris-i-and-ii-forearm-fractures-in-children-100451303","NCT05156749","Short and Long-arm Fiberglass Cast Immobilization for Distal Salter Harris I and II Forearm Fractures in Children","Unterarm-Combicast Versus Oberarm-Combicast Bei Gelenknahen Distalen (Salter Harris I\u002FII) Radius- Und Vorderarmfrakturen im Kindesalter","Inclusion Criteria:\n\n* Salter Harris I or II fracture of the distal radius or a forearm fracture\n* informed consent\n\nExclusion Criteria:\n\n* open\u002Finstable\u002Fintraarticular fracture\n* age \\\u003C4 years or \\> 16years\n* no informed consent","4 Years","16 Years",{"count":75,"type":20},120,"INTERVENTIONAL",[78],"NA","The aim of this study is to investigate whether short-arm fiberglass cast (SAC) immobilization provides fracture stabilization comparable to that of long-arm cast (LAC) treatment of displaced and non-displaced distal Salter Harris I\u002FII forearm fractures in paediatric patients.",[81],"Fracture Forearm","2026-04-29",{"date":84,"type":32},"2026-05-05",{"date":86,"type":32},"2021-12-07",{"date":88,"type":20},"2026-12-31",{"name":38,"class":39},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":76,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100581592","save-the-ovaries---surgical-management-of-simple-ovarian-cysts-in-children-and-adolescents-100581592","NCT06852313","Save the Ovaries - Surgical Management of Simple Ovarian Cysts in Children and Adolescents","Inclusion Criteria:\n\n* Symptomatic simple cysts ≥ 4 cm with indication for surgical intervention\n* Asymptomatic cysts ≥ 4 cm, with surgical indication due to persistence or increase in size\n* Asymptomatic cysts ≥ 4 cm with other pathology as surgical indication, if known preoperatively\n* Age 12 months - 18 years\n* Parents\u002Flegal custodian and patient give consent, for patients unable to consent due to their health condition or developmental status they show no signs of unwillingness to participate\n* Symptomatic simple cysts ≥ 4 cm with indication for surgical intervention on both ovaries (each ovary will count as one)\n\nExclusion Criteria:\n\n* Neonatal ovarian cysts (age \\\u003C12 months)\n* Age \\>18 years\n* Complex cysts (with solid components, e.g., Teratoma, risk or suspicion of malignancy)\n* Paratubar\u002Fparaovarian cysts\n* Medical reason that precludes cyst enucleation (e.g. severe coagulopathy)\n* Neither signed informed consent form or inadequate german, french or english language skills to give informed consent","FEMALE","1 Year","18 Years",{"count":100,"type":20},80,[78],"The purpose of this study is to evaluate which operative technique should be used for managing simple ovarian cysts in girls and adolescents. The two techniques that are being compared are laparoscopic cyst enucleation and laparoscopic cyst deroofing. The investigators will assess the effect of both techniques on the ovarian reserve and the risk of cyst recurrence.",[104],"Ovarian Cyst Benign",[106,107,108],"Ovarian cyst","Laparoscopy","Child","2026-04-27",{"date":111,"type":32},"2026-04-28",{"date":113,"type":32},"2026-02-05",{"date":115,"type":20},"2028-12-01",{"name":38,"class":39},2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":48,"sex":17,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":130,"studyType":21,"phases":4,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":64},"100519581","borrelia-b-cell-diagnostics-100519581","NCT06045416","Borrelia B-cell Diagnostics","Extensive Investigation of Immune Responses Against Borrelia Burgdorferi to Improve Diagnosis of Lyme Disease in Children: an Observational Study (BRILLIANT Study)","BRILLIANT","Inclusion Criteria:\n\n* Patients presenting at the ED with differential diagnosis of LD according to the treating physician\n\nExclusion Criteria:\n\n* Patients will be excluded in cases of primary or secondary immunodeficiency","1 Month","17 Years",{"count":129,"type":20},502,"6 Months","The investigators propose a single center, prospective observational study in children with Lyme disease (LD), the Borrelia B-cell diagnostics (BRILLIANT) study, to assess the immune response against Borrelia burgdorferi (Bb) with the following main objectives:\n\n1. Development of Bb-specific ASC ELISpot as a new test method for diagnosis of early LD.\n\n   There is an urgent unmet clinical need for a better diagnostic tool for early LD, as the current standard two-tier testing has low sensitivity in recently infected patients and may show false positive results in recovered patients due to long-term persistence of antibodies against Bb. The measurement of Bb-specific ASC with the ELISpot assay my has the potential to overcome these issues and to improve diagnosis in early LD.\n2. Extensive analysis of the immune response in LD. The immune response in LD is not well understood. Large-scale studies assessing the detailed immune cell subsets\u002Fphenotypes present in blood, CSF, or synovial fluid of LD patients with respective manifestations are lacking.\n3. Isolation and characterization of causative Bb species. Existing literature suggests that Bb genospecies and\u002For genotypes may determine virulence and manifestations, but large-scale studies assessing Bb genospecies\u002Fgenotypes in different manifestation of LD are lacking.\n4. Collection of clinical data about symptoms, severity, routine laboratory and diagnostic test results, treatment, and outcome of LD.\n5. Biobanking samples for analysis in the future.\n\nProject population\n\nInclusion criteria: Children, 0-17 years of age, at University Children's Hospital Zurich:\n\n* LD differential diagnosis cohort: Patients presenting at the ED with differential diagnosis of LD according to the treating physician.\n* Control cohort: Previously healthy patients (HC) with routine blood investigations presenting at the ED or PID outpatient department\n\nExclusion criteria: Primary or secondary immunodeficiency.",[133,134],"Lyme Disease","Borrelia Infections",[136,137,138,139],"Borrelia burgdorferi","Lyme disease","Borrelia specific ASCs","Borrelia strains",{"date":111,"type":32},{"date":142,"type":32},"2024-04-02",{"date":144,"type":20},"2028-11-01",{"name":38,"class":39},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100535758","clinical-and-histological-study-of-a-novel-dermal-substitute-100535758","NCT06255990","Clinical and Histological Study of a Novel Dermal Substitute","Clinical and Histological Study of a Novel Dermal Substitute, NovoSorb® BTM, Used in the Treatment of Full-thickness Skin Defects","Inclusion Criteria:\n\n* Age: 1 to 75 years\n* Full-thickness skin defect qualifying for coverage with the dermal substitute NovoSorb® BTM before transplantation with a STSG:\n\n  * Acute cases: burn injury, soft tissue injury, skin necrosis after purpura fulminans or similar condition\n  * Reconstructive cases (elective surgery): e.g. scar formation after burn injury, giant congenital nevus, defect after removal of skin tumor, skin defect due to other surgical procedures\n* Documented medical treatment decision of covering the full-thickness skin defects with either the two-step BTM\u002FSTSG procedure or with STSG alone or by using both techniques on different wound areas\n* Informed consent by patients\u002Fparents or other legal representative\n\nExclusion Criteria:\n\n* Infected wounds needing surgical procedure other than a dermal template\n* Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. immune deficiency, systemic skin disease, any kind of congenital defect of metabolism including diabetes)\n* Previous enrolment of the patient into the current study\n* Adolescent\u002FAdult patients or in case of children their parents\u002Flegal representatives unable to comply with the study protocol\n* Pregnant or breast feeding females","75 Years",{"count":155,"type":20},42,"The goal of this observational study is to compare a novel dermal substitute to a the current standard procedure in the treatment of full thickness skin defects.\n\nThe main questions aim to answer are:\n\n• Is the skin elasticity treated with the novel dermal substitute better than the skin elasticity treated with the current standard procedure Participants skin elasticity will be measured by Cutometer® MPA-580 assessment.",[26],"2026-03-30",{"date":160,"type":32},"2026-04-03",{"date":162,"type":32},"2024-01-15",{"date":164,"type":20},"2027-06",{"name":38,"class":39},4,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":73,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":64},"100230691","quality-of-life-and-stigmatization-in-children-with-congenital-melanocytic-nevi-before-and-after-nevus-excision-100230691","NCT02280889","Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision","Quality of Life and Experience of Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision: a Prospective Study","Inclusion Criteria:\n\n* patients with a congenital melanocytic nevi of at least 2 cm2 that will be removed surgically\n* age between 9 months and 16 years\n\nExclusion Criteria:\n\n* mental retardation of the child\n* insufficient knowledge of the German language of both parents\n* severe comorbidities\n* previous therapies done for the CMN (dermabrasion, surgery, laser)","9 Months",{"count":176,"type":20},100,"Congenital melanocytic nevi (CMN) are a quite common congenital disorder. Over years, surgical excision was proposed to the patients because transformation into a malignant skin tumor (melanoma) was feared. Recent data proof that the risk for malignancy was overestimated. Nowadays still a lot of patients express their wish for surgical removal out of aesthetic reasons and psychological impacts. Many patients and families experience stigmatization because of the nevus. To proof a medical indication for surgical removal the investigators want to evaluate the quality of life and stigmatization before and after nevus surgery.",[179,180],"Quality of Life","Stigmatization",[182,183,184,185],"quality of life","nevus or scar","stigmatization","scar","2026-03-02",{"date":188,"type":32},"2026-03-04",{"date":190,"type":32},"2013-05",{"date":192,"type":20},"2031-12",{"name":38,"class":39},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":201,"maxAge":98,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":64},"100623903","evaluating-symptom-variations-and-observing-longitudinal-individual-change-effects-in-tf-cbt-100623903","NCT07402681","Evaluating Symptom Variations and Observing Longitudinal Individual Change Effects in TF-CBT","EVOLVE","Participants will be included if:\n\n1. they are between 12 and 18 years of age;\n2. they have been exposed to at least one or more traumatic event(s) according to the DSM-5 A criteria after the age of 3 years and dating back at least 1 months (with regard to the ability of patients to remember the event(s) and to the high spontaneous remissions of PTSS in the first month after a traumatic event);\n3. they exhibit high severity of DSM-5 PTSS as indicated by a total symptom score of ≥25 assessed with the Child and Adolescent Trauma Screen 2 (CATS-2);\n4. a nonoffending adult caregiver is available for the treatment and willing to participate in weekly treatment sessions (the inclusion of a caregiver is integral to the TF-CBT treatment model);\n5. they are willing and able to attend weekly treatment sessions;\n6. if their living circumstances are safe and stable to minimize the risk of re-traumatization during the project;\n7. they and their caregiver have sufficient command of the German language (i.e., to participate in assessment \\[read\\] and treatment\\[converse\\]);\n8. they and their caregivers possess a smartphone.\n9. they and their caregiver provided written informed consent.\n\nParticipants will not be included if:\n\n1. they exhibit acute suicidal behavior or have suicidal ideations requiring immediate hospitalization;\n2. they have a documented developmental disorder (i.e., autism spectrum disorder) or current psychosis based on adolescent- and caregiver-report and clinical assessment;\n3. they exhibit severe substance misuse based on clinical assessment;\n4. take part in concurrent psychotherapy during TF-CBT;\n5. exhibit severe intellectual disability based on clinical assessment.","12 Years",{"count":203,"type":20},21,"The goal of this observational study is to learn about the level of change in post-traumatic stress symptoms in adolescents with traumatic experiences over the course of trauma-focused cognitive behavioral therapy for children and adolescents according to Cohen, Manarinno, \\& Deblinger (2017).",[206],"Post-traumatic Stress Symptoms",[208,209,210],"TF-CBT","post-traumatic stress symptoms","single-case experimental design","2026-02-04",{"date":213,"type":32},"2026-02-11",{"date":215,"type":20},"2026-02",{"date":62,"type":20},{"name":38,"class":39},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":48,"sex":17,"minAge":225,"maxAge":98,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},"100621249","development-of-the-ptsd-impact-to-measure-ptsd-related-functional-impairment-in-children-and-adolescents---a-validation-study-in-switzerland-and-germany-100621249","NCT07368166","Development of the PTSD-iMPACT to Measure PTSD-Related Functional Impairment in Children and Adolescents - A Validation Study in Switzerland and Germany","PTSD-iMPACT","Clinical population\n\nInclusion Criteria:\n\n* Use of (mental) health services at a participating study center.\n* Children and adolescents between 7 and 18 years \u002F caregivers of children and adolescents between 3 and 18 years\n* Sufficient knowledge of the German language\n* Signed consent form (7-18 years: patient and caregiver; 3-6 years: caregivers)\n\nExclusion Criteria:\n\n* Children and adolescents under 7 or over 18 years \u002F caregivers of children and adolescents under 3 or over 18 years\n* Not sufficient knowledge of the German language\n* No signed consent form (7-18 years: patient and\u002For caregiver; 3-6 years: caregivers)\n\nNon-clinical population Only recruited in Switzerland.\n\nInclusion Criteria:\n\n* Students between 3rd grade and 18 years \u002F caregivers of kindergarteners and students up until 18 years\n* Sufficient knowledge of the German language\n\nExclusion Criteria:\n\n* Students 2nd grade or lower and over 18 years \u002F caregivers of children not yet in Kindergarten and students over 18 years\n* No sufficient knowledge of the German language","7 Years",{"count":227,"type":20},1200,"Population-based and clinical studies indicate that a substantial proportion of children and adolescents are exposed to one or more potentially traumatic events (PTEs) Approximately 16 % of those affected by childhood trauma go on to develop post-traumatic stress disorder (PTSD), with an even higher proportion experiencing subclinical levels of post-traumatic stress symptoms (PTSS). In Switzerland, over half of adolescents report exposure to at least one PTE, with 4.2 % meeting diagnostic criteria for PTSD. PTSD frequently impacts young people's social and educational functioning, often impairing their ability to engage in everyday life activities that are important or meaningful to them. Although the psychological consequences of PTSD are well documented, there is limited empirical understanding of how PTSS specifically affects day-to-day functioning in young people.\n\nA key reason for this gap is the absence of a validated instrument specifically designed to assess PTSD-related functional impairment in children and adolescents. To address this need, the PTSD-iMPairment in Adolescent \\& Children's Capacity for Thriving (PTSD-iMPACT) measure was developed. This tool aims to systematically assess the extent of PTSD-related functional impairment in children and adolescents across key life domains, such as family, friends, school, apprenticeship, hobbies or media use.\n\nThe overall aim of this study is to evaluate the psychometric properties of the PTSD-iMPACT questionnaire in a clinical and in a non-clinical sample and to provide an internationally applicable standard instrument for the assessment of PTSD-related functional impairment in trauma-exposed children and adolescents.\n\nIn the long term, the aim is to ensure that the care and support provided to children and adolescents who experience difficulties in their daily lives due to post-traumatic stress symptoms are sustainably monitored and improved.",[230,231],"PTSD - Post Traumatic Stress Disorder","PTSD-Related Functional Impairment in Children and Adolescents",[233,234,235,223,236,237,238],"PTSD","PTSS","Functional Impairment","Validation","Posttraumatic stress disorder","Posttraumatic stress symptoms","2026-01-20",{"date":241,"type":32},"2026-01-26",{"date":243,"type":32},"2025-12-15",{"date":245,"type":20},"2026-10-31",{"name":38,"class":39},11,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":48,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":76,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":64},"100490864","ureagenesis-analysis-in-healthy-subjects-and-in-urea-cycle-disorder-patients-100490864","NCT05671666","Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients","Inclusion Criteria:\n\n* healthy subjects at any age and given written informed consent\n* subjects with a UCD confirmed by genetic or enzymatic diagnostics at any age and given written informed consent\n\nExclusion Criteria:\n\n* healthy subjects with acute and chronic disease requiring treatment of any kind\n* pregnant or lactating women.\n* UCD patients with acute and chronic (other than her\u002Fhis UCD) disease requiring treatment\n* UCD patients in which intake of carglumic acid cannot be stopped for 24 hours prior to the test",{"count":176,"type":20},[78],"Urea cycle disorders (UCDs) are dramatic congenital inherited metabolic disorders. There is no cure. Many novel therapeutic approaches are currently being developed, which hopefully will change the current situation. Testing the efficacy of such new therapies in patients is a challenge, because many clinical parameters are influenced by several disturbances and biochemical parameters are often not very specific.\n\nThe measurement of ureagenesis is a tool to analyze the entire function of the urea cycle in a single test. This is more meaningful for the characterization of UCD patients than the analysis of single metabolites or enzymes. Therefore, the test will be important to evaluate current and future novel therapies.\n\nThe term \"ureagenesis\" means \"production of urea\", which is the main task of the urea cycle. This total urea production can be measured with a \"tracer\" (in this case a stable ammonium chloride isotope). This tracer is non-radioactive and non-toxic. It is for example used as an unmarked substance in cough syrup, diuretic drugs and as food additive. Thus, the tracer does not pose a risk to the participant, especially since only a very low dose is applied.\n\nThe investigators will analyze specific substances from the urea cycle (namely \\[15N, 14N\\] urea and several \\[15N\\] amino acids) that are produced during the test and compare them with results from healthy people. Venous and capillary blood will be sampled at 15 to 30 minutes intervals up to 2 hours after administration of the stable isotope tracer. The maximum test duration is 5 hours.\n\nThis project is being carried out at one site, namely the University Children's Hospital in Zurich.\n\nThis project is being carried out under Swiss law. The responsible Ethics Committee has reviewed and approved the study.",[258],"Urea Cycle Disorders","2026-01-05",{"date":261,"type":32},"2026-01-08",{"date":263,"type":32},"2019-10-31",{"date":265,"type":20},"2035-12-31",{"name":38,"class":39},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":275,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":64},"100558860","health-related-quality-of-life-hrqol-in-classical-homocystinuria-cbs-deficiency-100558860","NCT06556615","Health Related Quality of Life (HrQoL) in Classical Homocystinuria (CBS Deficiency)","Development and Validation of a Standardized Assessment Instrument for Health-related Quality of Life (HrQoL) in Patients With Classical Homocystinuria","CBS_HrQoL","Inclusion criteria\n\n* Patients with CBS deficiency from age 8 years\n* Parents of patient(s) \\\u003C 18 years with cognitive impairment\n* Parents of patients between age 4 and 7\n* Experts on CBS deficiency\n* Able to give informed consent as documented by signature\n\nExclusion criteria\n\n\\- Sufficient command of the German or the English language","8 Years",{"count":100,"type":20},"Patients, parents of young \u002F handicapped patients, and experts will be interviewed to collect contents relevant for HrQoL in CBS deficiency. Based on these data, a questionnaire will be developed and tested for comprehensibility in patients and parents of young \u002F handicapped patients. A final questionnaire version will be tested for psychometric criteria including validity and reliability.",[279],"Homocystinuria","2025-04-09",{"date":282,"type":32},"2025-04-10",{"date":284,"type":32},"2025-01-15",{"date":286,"type":20},"2025-09",{"name":38,"class":39},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":64},"100449105","metabolic-control-and-patient-well-being-in-phenylketonuria-do-guidelines-make-a-difference-100449105","NCT05128149","Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?","PKU_Guide","Inclusion Criteria:- Patients with PKU from age 10 years requiring dietary and \u002F or pharmacological treatment according to locally applied guidelines\n\n* Parents of patients with PKU aged 10 to 18 years requiring dietary and \u002F or pharmacological treatment according to locally applied guidelines\n* Ability and willingness to answer the questionnaires and follow the study procedures\n* Informed consent as documented by signature\n\nExclusion criteria for patients and parents :\n\n* Inability to follow the procedures of the study, e.g. due to language problems or severely reduced health status\n* Pregnant patients or patients who have disclosed to their physician that they are planning a pregnancy in the near future\n* Hyperphenylalaninaemia or mild forms of PKU or other inborn errors associated with elevated Phe but not requiring dietary and \u002F or pharmacological treatment according to locally applied guidelines\n* No inform","10 Years",{"count":297,"type":20},200,"Treatment of PKU implies for most patients that with strict adherence to dietary treatment they can achieve excellent neurocognitive outcome. Dietary treatment, though, is hard to comply to every day and with every single meal. Unsurprisingly, health-related quality of life (HrQol) is negatively affected if patients have to follow a dietary regime of this kind. Adherence to treatment in PKU is very variable. Factors of significant impact on adherence to treatment and well-being in chronic disease such as self-efficacy or parenting stress have not yet been widely investigated in PKU patients.\n\nThe ideal treatment prescription (and guideline) recommends as much as necessary and as little as possible, based on the best evidence available. Patients should neither be deprived of treatment options nor be exposed to overtreatment.\n\nThis study investigates adherence, metabolic control, HrQol in PKU patients treated by centres which follow different guidelines",[300],"Phenylketonurias",{"date":302,"type":32},"2025-04-13",{"date":304,"type":32},"2021-11-15",{"date":306,"type":20},"2025-12-31",{"name":38,"class":39},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":316,"maxAge":98,"enrollmentInfo":317,"targetDuration":4,"studyType":76,"phases":319,"briefSummary":320,"conditions":321,"keywords":324,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":40},"100568024","an-innovative-endoscopic-cap-for-dilating-benign-esophageal-strictures-in-children-100568024","NCT06675825","An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children","A Novel Endoscopic Attachment Cap for Benign Esophageal Stricture Dilation in Children: a Randomized, Multicentric Pilot Study.","BOUGIE-PED","Inclusion Criteria:\n\n* Age under 18 years of age\n* Indication for endoscopic esophageal dilation\n* Benign stenosis\n* Written Informed Consent signed by the subject and\u002For parent\u002Flegal representative (if applicable)\n\nExclusion Criteria:\n\n* Stenosis that cannot be treated endoscopically\n* Malignant esophageal strictures\n* Contraindications and limitations of the MD as described in the instructions for use","0 Years",{"count":318,"type":20},40,[78],"The goal of this study is to find out if using the BougieCap device is a safe and effective way to stretch narrow areas in the esophagus (food pipe) in children. The main questions this study wants to answer are:\n\n* Does the BougieCap work well to treat narrow areas in the esophagus comparing with other methods to widen these narrow areas?\n* Is BougieCap easy to use and does it cause fewer problems or discomfort for children?\n\nResearchers will compare two groups: one using the BougieCap, and the other using traditional methods like balloon dilation, to see which one works better and is safer.\n\nParticipants will:\n\n* Answer questions about their symptoms before treatment, 24 hours after, and 14 days later.\n* Complete these questions during regular hospital visits or over the phone for the final check-up.\n\nThis study does not involve any extra risks or burdens for the participants.",[322,323],"Esophageal Stenosis","Esophageal Dilation",[325,326,327],"esophageal stricture","esophageal dilation","pediatric gastroenterology","2024-12-10",{"date":330,"type":32},"2024-12-11",{"date":332,"type":20},"2025-01",{"date":334,"type":20},"2026-12",{"name":38,"class":39},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":48,"sex":17,"minAge":343,"maxAge":98,"enrollmentInfo":344,"targetDuration":4,"studyType":76,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":64},"100421616","auditory-slow-wave-enhancement-after-concussion-100421616","NCT04770116","Auditory Slow Wave Enhancement After Concussion","The Effect of Sleep and Slow Wave Enhancement on Recovery From a Concussion in Children and Adolescents: A Longitudinal, Randomized, Double-Blind, and Sham-Controlled Study","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Age between 6 and 18 years\n* Good knowledge of German of the patient and at least one legal representative\n* Patients: Presentation to the Emergency of the University Children's Hospital Zurich because of a concussion (diagnosed by medical doctor)\n\nExclusion Criteria:\n\n* Preterm birth (\\\u003C 37 gestational weeks)\n* Diagnosed hearing disorder\n* Psychiatric, syndromal, or neurological pre-existing condition (except for previous concussion)\n* Skin disorder\u002Fskin problem in the face\u002Fear area that requires Treatment\n* Usage of neuroactive substances\n* Patients: Concomitant injury that requires intense pain medication or a prolonged hospital stay, or that causes limited use of the dominant Hand\n* Patients: Previous moderate-severe TBI\n* Controls: Injury of the dominant hand, on head, arm, or leg\n* Controls: Previous TBI (of any severity)\n\nAdditional inclusion criteria for the optional MRI measurement for both groups:\n\n* Age at least 8 years\n* Fulfilment of all MRI safety criteria\n* The participant and the legal representative would want to know about incidental findings.\n* Girls: No pregnancy or breast feeding.","6 Years",{"count":75,"type":20},[78],"The prevalence of a traumatic brain injury (TBI) in children and adolescents is around 30% with 70-90% being classified as mild (concussion). Because the brain of a child is still developing, a TBI can have devastating effects and possibly creates lifetime challenges. Sleep seems to play an important role in the post-concussion recovery process. Auditory stimulation during sleep has been shown to reliably boost slow waves, a solid marker for the depth of sleep, and can thus be used to deepen sleep. This study aims to investigate the effects of sleep enhancement via auditory stimulation on recovery after a concussion in children and adolescents in their home. Therefore, half of the patients receive one week of auditory stimulation during deep sleep at their home using a mobile device. The other half follows the same study protocol, but no tones are administered (sham). Cognitive tests as well as symptom questionnaires are used to assess the recovery process. It is hypothesized that the patients in the intervention group will recover better than the ones who haven't received the intervention. Additionally, a group of children and adolescents who never sustained a concussion is included as a control.",[348],"Concussion Post Syndrome",[350,351,352,353],"sleep","auditory stimulation","post-concussive symptoms","in-home EEG","2024-12-04",{"date":356,"type":32},"2024-12-09",{"date":358,"type":32},"2021-05-31",{"date":360,"type":20},"2026-03-31",{"name":38,"class":39},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":369,"enrollmentInfo":370,"targetDuration":295,"studyType":21,"phases":4,"briefSummary":372,"conditions":373,"keywords":375,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":64},"100558360","drug-response-profiling-drp-registry-zurich-for-hematological-malignancies-100558360","NCT06550102","Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies","DRP_ZH","Inclusion Criteria:\n\n* Pediatric and adult patients below the age of 40 years\n* Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma\n* Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research\n* Patient and\u002For guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.\n\nExclusion Criteria:\n\n* Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research","40 Years",{"count":371,"type":20},1000,"This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.",[374],"Hematological Malignancies",[376,377,378,379],"registry","DRP","acute lymphoblastic leukemia","blood cancer","2024-08-12",{"date":382,"type":32},"2024-08-15",{"date":384,"type":32},"2022-01-04",{"date":386,"type":20},"2031-12-31",{"name":38,"class":39},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":17,"minAge":395,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":76,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":411},"100471008","targeted-interventions-for-successful-transition-and-transfer-of-adolescents-with-inborn-errors-of-metabolism-to-adult-services-100471008","NCT05413278","Targeted Interventions for Successful Transition and Transfer of Adolescents With Inborn Errors of Metabolism to Adult Services","Fit for Transfer: Targeted Interventions for Successful Transition and Transfer of Adolescents With Inborn Errors of Metabolism to Adult Metabolic Services","Inclusion Criteria:Patients\n\n* with an inborn error of metabolism in the care of a specialized metabolic care unit\n* requiring specialized adult metabolic care\n* at least 14 years old\n* with a disease for which at least one biochemical and \u002F or physical parameter disease marker is well established .\n\nExclusion Criteria:\n\nPatients -\n\n* with insufficient knowledge of the German\n* with cognitive impairment to a degree that consent, and participation would be impossible\n* in an end-of-life situation\n* with a disease for which no biochemical and \u002F or physical parameter disease marker is well established","14 Years","25 Years",{"count":398,"type":20},20,[78],"Main aims of this project are\n\n* To assess the baseline status-quo of transition and \"fitness for transfer\" in terms of information about the adult centre and team, organisational and practical skills (blood sampling and sending, how to make an appointment etc.), disease- and treatment-related knowledge, health-related quality of life (HrQoL), and self-efficacy in adolescnets with inborn errors of metabolism. Biochemical or physical parameters as appropriate for the respective diseases from 12 months before are documented.\n* To provide targeted, structured intervention modules (using available and, if necessary, adapted materials).\n* To measure the effects of these interventions on information about adult services short-term (within a month) and to re-assess all other baseline status-quo parameters long-term (6 and 12 months later). Psychological assessments will be complemented by biochemical or physical parameters as appropriate for the respective diseases and indicative for transition success.",[402,403],"Transition","Inborn Errors of Metabolism","2024-08-05",{"date":406,"type":32},"2024-08-06",{"date":408,"type":32},"2024-01-01",{"date":306,"type":20},{"name":38,"class":39},8,{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":48,"sex":17,"minAge":4,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":76,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":64},"100513883","comparison-of-bladder-pressure-versus-regional-intestinal-tissue-oxygenation-in-infants-100513883","NCT05971264","Comparison of Bladder Pressure Versus Regional Intestinal Tissue Oxygenation in Infants","BPvsNIRS","Inclusion Criteria:\n\n* Prepped and consented for laparoscopic pyeloplasty or minimal PSARP with perineal or vestibular fistula or lateral thoracotomy for the correction of esophageal atresia\n* Age of 12 months old or less at operation\n* Legal custodian gives consent\n\nExclusion Criteria:\n\n* Anterior abdominal wall thickness greater than 12 mm measured on preoperative MRI imaging if available\n* Patients planned for additional intestinal surgeries or non-standard pyeloplasty, e.g. pyeloplasty with nephrostoma\n* Patients planned for laparoscopic pyeloplasty whose intraoperative urine sample shows pathological results\n* Patients with esophageal atresia who experience pulmonary decompensation and need urgent surgery for fistula clipping","12 Months",{"count":421,"type":20},30,[78],"The goal of this clinical trial is to learn more about intestinal regional oxygen saturation measurements made with near-infrared spectroscopy and bladder pressure measurements in infants without risk of intraabdominal hypertension. The main question it aims to answer is if - in comparison to bladder pressure - the regional intestinal oxygen saturation measured with near-infrared spectroscopy is stable in the muscle-relaxed, intubated patients and the awake and non-sedated patient.\n\nIn case of participation the bladder pressure and the regional intestinal oxygen saturation (measured with near-infrared spectroscopy) will each be measured once intraoperatively and once postoperatively. Patients included in this study will be undergoing an operation which necessitates muscle-relaxation, as well as an indwelling urinary catheter during the operation and for a short-time thereafter for other reasons than this study.",[425,426],"Intraabdominal Hypertension","Abdominal Compartment Syndrome",[428,429,430],"Near infra-red spectroscopy","Bladder pressure","Intraabdominal pressure","2024-04-24",{"date":433,"type":32},"2024-04-25",{"date":435,"type":20},"2024-05-01",{"date":437,"type":20},"2026-06-30",{"name":38,"class":39},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":17,"minAge":446,"maxAge":447,"enrollmentInfo":448,"targetDuration":295,"studyType":21,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":40},"100515800","the-swiss-neurodevelopmental-outcome-registry-for-children-with-chd-100515800","NCT05996211","The Swiss Neurodevelopmental Outcome Registry for Children With CHD","SwissORCHID","Inclusion Criteria:\n\n* Neonates (including preterm born children) with severe CHD\n* Requiring an invasive cardiac intervention (including heart-lung-machine) within the first 6 weeks of life.\n\nExclusion Criteria:\n\n* Neonates (including preterm born children) with simple CHD\n* Requiring simple cardiac surgery or catheter intervention such as closure of patent arterial duct or simple repair of aortic coarctation without heart-lung-machine and low impact on neurodevelopmental outcome.","1 Week","6 Weeks",{"count":371,"type":20},"Introduction: Congenital heart disease (CHD) is the most frequent birth defect. As survival has significantly improved, attention has turned to neurodevelopmental outcomes of children undergoing heart surgery in early infancy. Since multiple risk factors contribute to neurodevelopmental alterations, a nationwide registry collecting data on medical characteristics, interventions, clinical course and neurodevelopment until school-age is needed to improve the quality of management, identify risk- and protective factors affecting neurodevelopment, and facilitate multicenter trials.\n\nMethods and analysis: The Swiss Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is a nationwide, prospective, population-based patient registry developed (1) to collect baseline characteristics and clinical data of CHD patients operated with bypass-surgery or hybrid procedures in the first 6 weeks of life in Switzerland, (2) to monitor long-term neurodevelopment, and (3) to relate clinical characteristics and neurodevelopment to identify risk and protective factors in these children. This registry started data collection relating to pregnancy, birth, preoperative course, catheter-based and surgical treatment, postoperative course and reinterventions in 2019. The primary outcome includes standardised neurodevelopmental assessments at 9 to 12 months, 18 to 24 months and 5.5 to 6 years. Investigators expect to include 80 to 100 children per year. Correlation and regression analyses will be used to investigate risk- and protective factors influencing neurodevelopment.\n\nEthics and dissemination of results: Swiss ORCHID received support by the Accentus Charitable Foundation, the Anna Mueller Grocholoski Foundation, the Swiss Society of Pediatric Cardiology, and the Corelina - Foundation and was approved by the cantonal ethics committees. Findings will be presented at national and international scientific meetings, and published in peer-reviewed journals. Results will also be shared with patient organizations, primary health care providers, and public health stakeholders to ensure a widespread dissemination of the results.",[451,452,453,454],"Neurodevelopmental Abnormality","Congenital Heart Disease","Cardiac Disease","Intensive Care Neurological Disorder","2023-08-08",{"date":457,"type":32},"2023-08-18",{"date":459,"type":32},"2019-01-01",{"date":461,"type":20},"2032-12-31",{"name":38,"class":39},{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":17,"minAge":471,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":76,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":64},"100493211","creative-music-therapy-in-newborns-with-congenital-heart-disease-100493211","NCT05702203","Creative Music Therapy in Newborns With Congenital Heart Disease","Creative Music Therapy in Newborns With Congenital Heart Disease: A Randomized Clinical Trial","BOND","Inclusion Criteria:\n\n* All newborn infants with CHD born \\>35 weeks of gestational and \\\u003C28 days at diagnosis of CHD irrespective of severity of the heart disease\n* Admitted to Neonatal Intensiv Care Unit\u002FPediatric Intensiv Care Unit (NICU\u002FPICU) at the Children's University Hospital\n* Infants with syndromes and \u002For confirmed chromosomal abnormalities\n\nExclusion Criteria:\n\n\\- Gestational age at birth \\\u003C35 weeks, age \\>28 days at diagnosis of CHD","1 Minute","28 Days",{"count":474,"type":20},164,[78],"In the context of a clinical trial, the investigators will evaluate if parent-infant interaction can be improved by a family integrated, individualised, interactive resource- and needs-oriented music therapy approach in the dyads of infants with congenital heart disease and their parents.\n\nThis intervention will be compared with the standard of care. Infants allocated to the control group will receive standard care during admission. Standard care includes involvement of a multi-professional team consisting of medical and nursing team, psychologists\u002Fpsychiatrists, social workers, breastfeeding counsellor, speech therapist, nutritional counsellor and physiotherapists.",[452,478],"Mother Child Interaction",[480,481],"Parental mental health","Magnetic resonance Imaging","2023-01-17",{"date":484,"type":32},"2023-01-27",{"date":486,"type":32},"2022-11-22",{"date":488,"type":20},"2026-10-24",{"name":38,"class":39},""]